

28-30 November 2018
Loews Coronado Bay Resort, San Diego, USA

Integrating the technologies revolutionising immunotherapy and its impact on vaccines development

PART OF

CREATED BY

Introducing the World Vaccine & Immunotherapy Congress

After an incredibly successful inaugural year, the World Vaccine and Immunotherapy Congress is back in 2018 to bring you more content, learning and business development opportunities so you can take advantage of the rich biotech and funding environment that the West Coast offers.

Whilst still focussing on the vaccine and immunotherapy industry the scope of the event has expanded considerably and will delve deeper into topics surrounding vaccine development, cancer immunotherapy, funding and partnerships as well as exploring new topics in clinical trials & development,

bioprocessing, manufacture and delivery, and the development and use of antibodies for both infectious diseases and cancer.

This is the congress for top decision makers of the vaccine and immunotherapy industry with both scientific and commercial interests,

specifically interested in both learning and/or partnering.

No matter where your interest lies we have content, networking and potential partners for you.

WHAT TO EXPECT?

Providing attendees one stop progressive scientific and strategic solutions to the vaccine and immunotherapy industry, through executive level commentary, case studies and real-time analysis from key stakeholders to bring about faster, more cost-effective and more efficacious vaccines.

- Meet the key players from the Human Vaccines Project - including all five universities and academics centers involved as well as senior members of the Scientific Steering Committee.
- Hear exciting research from some of the top cancer centers in the US as well as senior representatives of leading consortia, including the Parker Institute for Cancer Immunotherapy, the San Diego Center for Precision Immunotherapy, the California Institute for Biomedical Research and the MD Anderson Cancer Center amongst others.
- Explore the latest methods and technologies that allow better understanding of the immune system and improve vaccine development and other immunotherapy approaches against infectious diseases

and cancer. This includes integrating synthetic biology, omics, immune profiling, bioinformatics, systems biology and new-generation adjuvants with break through immunotherapy immunomodulators like check point inhibitors and oncolytic viruses in combinational therapies.

- Hear from C-Level executives from all the key vaccine developers and thought leaders from pharma, biotech's, academics and government, in a combined scientific and commercial environment where CRO's, CMO's, EQM's, Biotech's and platform technology organisations can demonstrate their latest products and services and do business.
- Listen to updates on the latest discovery-stage infectious and non-infectious vaccines and hear clinical phase I, II and III data from leading biotech's, big pharma and regulatory experts.
- Discover new technology for the manufacture, delivery and administration of vaccines, considerations for the manufacture of novel immunotherapies and engineered antibody formats.



Dr Biol. Sci. Alessandro Sette

Center Head, Division Head, and Professor Center for Infectious Disease
La Jolla Institute



Dr Karin Jooss

Executive Vice President of Research, and Chief Scientific Officer
Gritstone Oncology



Dr Jerald Sadoff

Senior Advisor
Janssen Infectious Diseases and Vaccines



Prof Bali Pulendran

Professor in the Department of Pathology, and Microbiology & Immunology
Stanford University School of Medicine



Dr Ezra Cohen

Professor of Medicine
UC San Diego Moores Cancer Center, Co-Director, San Diego Center for Precision Immunotherapy



Dr Peter Hotez

MD PhD, Professor and Director, Texas Children's Hospital Center for Vaccine Development, and Dean of the National School of Tropical Medicine, Baylor College of Medicine



Dr Roy Baynes

Senior Vice President Global Clinical Development and Chief Medical Officer
Merck Research Laboratories



Dr Wayne C. Koff

President and CEO - The Human Vaccines Project



Dr Maria Karasarides

Executive Director, ImmunoOncology
Regeneron Pharmaceuticals

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

Meet Key Vaccine & Immunotherapy Decision Makers



Dr Anna Durbin
Professor, International Health, Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health



Dr Asha Das
SVP & CMO
Tocagen Inc.



Dr Barry Datlof
Director Medical Technology Transfer and Intellectual Property
U.S. Army Medical Research and Materiel Command



Dr Bruce Gellin
President, Global Immunization
Sabin Vaccine Institute



Dr Christina Chambers
Professor of Pediatrics, Founding Principal Investigator
Vaccines and Medications in Pregnancy Surveillance System, UCSD



Dr Cristian Massacesi
VP, Immuno-Oncology Medicine Team
Leader, Global Product Development, Oncology
Pfizer Inc



Dr Eve Dubé
Associate professor, Department of Social and Preventive Medicine
Faculty of Medicine, Université Laval



Dr Farshad Guirakhoo
CSO
GeoVax



Dr James Crowe
Director
Vanderbilt Vaccine Center



Dr Janelle Ayres
Associate Professor, Nomis Center for Immunobiology & Microbial Pathogenesis
Salk Institute for Biological Studies



Dr Jayant Aphale
Executive Vice President
Technical Operations
Gritstone Oncology



Dr John Baldoni
Senior Vice President, DPU
Head, In Silico Discovery
GSK Pharmaceuticals



Dr John Dejarlais
Senior Vice President, Research and CSO
Xencor



Dr Kate Broderick
Vice President, Research & Development
Inovio Pharmaceuticals



Dr Keith Rubin
CEO
ILiAD Biotechnologies



Dr Kristen Hege
Vice President, Translational Development, Hematology/Oncology
Celgene



Dr Larry Smarr
Director
California Institute for Telecommunications and Information Technology



Dr Lisa Danzig
CMO
PaxVax



Dr Michael Mowatt
Director, Technology Transfer and Intellectual Property Officer
National Institute of Allergy and Infectious Diseases



Dr Min Song
Cancer Therapy Evaluation Program, Cancer Moonshot Implementation Team
National Cancer Institute, NCI



Dr Nancy Valente
Vice President, Global Product Development, Hematology/Oncology; Head Hematology Development
Genentech



Dr Niranjan Sardesai
COO
Inovio Pharmaceuticals



Dr Richard Koup
Deputy Director, Vaccine Research Center, Chief, Immunology Laboratory
NIAID, NIH



Dr Richard Pan
State Senator
6th District



Robb Butler
Former Program Manager, Vaccine-preventable Diseases and Immunization
World Health Organization



Dr Ron Babecoff
Founder, President & CEO,
BiondVax Pharmaceuticals



Sandrine Miller-Montgomery
Executive Director
Center for Microbiome Innovation



Dr Stephen Hoffman
CEO & CSO
Sanaria



Dr Steven Coats
Vice President, R&D
MedImmune



Dr Sushma Shivaswamy
CSO
XBiotech USA Inc.



Dr Ted Tsai
Vice President, Immunizations, Science and Policy
Takeda Vaccines



Dr Theresa LaVallee
Head of Translational Medicine
Parker Institute for Cancer Immunotherapy



Dr Teri Heiland
Co-Founder & Sr. Vice President of Research and Development
Immunomic Therapeutics



Dr Travis Young
Director, Protein Sciences
California Institute for Biomedical Research



Dr Vali Papdimitrakopoulou
Professor, Department of Thoracic/Head and Neck Medical Oncology, Co principle investigator Lung-MAP Trials
MD Anderson Cancer Center



Dr William Schief
Professor, Department of Immunology and Microbiology
The Scripps Research Institute

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

9 Reasons to Attend

- 1 New speakers announced for 2018! **Meet over 150 speakers** including Dr Nancy Valente (Genentech), Dr Anna Durbin (Johns Hopkins), Dr Bruce Gellin (Sabin), Dr Ted Tsai (Takeda Vaccines), Dr Cristian Massacesi (Pfizer), Dr Janelle Ayers (Salk), Dr Larry Smarr (Calit2) and many more!
- 2 New focus on antibody therapies including; development of antibody therapies for infectious diseases and cancer including monoclonal antibodies, bispecifics and antibody drug conjugate development from leaders in the industry; **Celegene, Genetech, Medimmune, NIAID, Rengeneron and others.**
- 3 Grow your business; meet with heads of the technology transfer units of **the Department of Defense** and **NIAID** and learn more about how you can partner with federal labs, **showcase your latest tech solutions** to a seasoned panel of investors and hear from big pharma on what they are interested in partnering in.
- 4 Understand the latest progress in **Universal Influenza Vaccine Development**; Vaxart, Medicago and BiondVax will provide clinical trial updates for their candidates whilst leaders in this space **Dr James Crowe** (Vanderbilt), **Dr Bruce Gellin** (Sabin) **Dr Jerald Sadoff** (Janssen) will provide insight into how we will integrate the knowledge gained from **the Universal Influenza Vaccine Initiative** in to the development of a universal vaccine.
- 5 Keep up-to-date with the latest developments in Immuno-Oncology from **cancer vaccine development, T-cell therapies, checkpoint inhibitors and combination therapy to neoantigen selection and biomarker discovery.**
- 6 A deeper dive into **immunotherapy clinical trial design and analysis**; what are the merits of basket and umbrella trial designs? How can they help reduce cost, improve patient access and accelerate development of therapies to patients? Hear from Leaders for **I-SPY2** and **LUNG-MAP** clinical trials.
- 7 **CEPI grant receipt Inovio** will provide insight into why their vaccine development platform has been selected to ensure we can respond quickly to the next pandemic threat.
- 8 Understand the impact of the **microbiome and tumor microenvironment** on the development of new therapies; leading academics from UCSD, The Parker Institute and industry representatives from Merck
- 9 **Now even more networking opportunities across 3 days**, you will have more time to meet over **300+ cross-industry representatives through drinks receptions, a dedicated exhibition area, extended breaks and 1-2-1 networking meetings** in one of the richest biotech environments in the world!

2018 Agenda Overview

DAY 1 - 28th NOVEMBER	DAY 2 - 29th NOVEMBER	DAY 3 - 30th NOVEMBER
PLENARY SESSIONS 	VACCINE DEVELOPMENT Nosocomial Vaccines & New Vaccine Targets IMMUNO-ONCOLOGY Therapeutic Immunotherapy Approaches DELIVERY, BIOPROCESSING & MANUFACTURING Vaccine Technology	VACCINE DEVELOPMENT Immune Profiling IMMUNO-ONCOLOGY Tumor Microenvironment and Tumor Host Interactions FUNDING & PARTNERSHIP Investment Opportunities
Networking Break	Networking Break	Networking Break
VACCINE DEVELOPMENT Respiratory Diseases Neglected & Emerging Diseases IMMUNO-ONCOLOGY Cancer Vaccine Development Therapeutic Immunotherapy Approaches CLINICAL TRIALS & DEVELOPMENT Trial design & Development Vaccine, Immunotherapy, Antibody Clinical Trials	ROUNDTABLES 	VACCINE DEVELOPMENT Immune Profiling IMMUNO-ONCOLOGY Tumor Microenvironment and Tumor Host Interactions FUNDING & PARTNERSHIP Investment Opportunities
Lunch	Lunch	Lunch
VACCINE DEVELOPMENT Respiratory Diseases Neglected & Emerging Diseases IMMUNO-ONCOLOGY Cancer Vaccine Development Therapeutic Immunotherapy Approaches CLINICAL TRIALS & DEVELOPMENT Trial design & Development Vaccine, Immunotherapy, Antibody Clinical Trials	VACCINE DEVELOPMENT Antibodies for infections Diseases/ Autoimmune IMMUNO-ONCOLOGY Antibodies for Cancer DELIVERY, BIOPROCESSING & MANUFACTURING Manufacturing Immunotherapies Antibody Technology & Delivery	PLENARY SESSIONS 
Networking Drinks Sessions	Networking Drinks Sessions	Networking Drinks Sessions

FOR WORLD CLASS SOLUTION PROVIDERS

The Vaccine & Immunotherapy Congress West Coast offers outstanding opportunities for service and solution providers, from senior sponsorship to a range of exhibition booths. If you are looking to gain access to key vaccine and immunotherapy decision makers then this is your best ROI in 2018.

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapiinn.com

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapiinn.com

DAY 1 AGENDA

PLENARY SESSION: THE BIG PICTURE		
08.00	Chair's opening remarks	
08.10	KEYNOTE OPENING ADDRESS The impact of vaccine legislation on public health in California	 Dr Richard Pan , State Senator 6th District
08.35	Addressing the epidemic of misinformation	MODERATOR: Robb Butler, Former Program Manager, Vaccine-preventable Diseases and Immunization, World Health Organization Dr David Gorski, Professor & Chief, Breast Surgery Section, Wayne State University School of Medicine; Managing Editor, Science Based Medicine Dr Eve Dubé, Researcher, Quebec National Institute of Public Health; Invited professor, Departement of Anthropology, Université Laval Dr Richard Pan, State Senator 6th District
09.20	Novel approaches to fighting infectious diseases and the increasing global threat of Anti-Microbial Resistance	 Dr Janelle Ayres , Associate Professor, Normis Center for Immunobiology & Microbial Pathogenesis, Salk Institute for Biological Studies
09.45	The evolution of antibody therapy for cancer	Dr Ho Cho, VP Biotherapeutics Executive Research, Celgene Dr Nancy Valente, Vice President, Global Product Development, Hematology/ Oncology, Head Hematology Development, Genentech
10.30	Morning Networking Break & Poster Session	
	VACCINE DEVELOPMENT	IMMUNO-ONCOLOGY
	RESPIRATORY DISEASES	CANCER VACCINE DEVELOPMENT
		CLINICAL TRIALS
		TRIAL DESIGN AND ANALYSIS
11.25	Chair's opening remarks	Chair's opening remarks
11.35	Advantages of using oral tablet vaccines for protection against influenza Dr Sean Tucker , CSO, Vaxart, Inc.	Synthetic DNA vaccines for cancer immunotherapy - Enabling CPI combinations and personalized treatments Dr Niranjan Sardesai , COO, Inovio Pharmaceuticals
12.05	Efficacy, Safety and immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults Nathalie Landry , EVP Scientific & Medical Affairs, Medicago	An off-the-shelf dendritic cell vaccine candidate for treatment of CMV+ tumors Dr David Anderson , CSO, VBI Vaccines
12.20		Tools to identify, predict and prioritize vaccine candidates Dr Amit Choudhuri , Vice President, Research & Development, MedGenome
12.35	DISCUSSION How will we integrate knowledge gained from the UIVI into the development of a Universal Influenza Vaccine?	Trials to determine optimal vaccine dose and regimen to maximize anti-tumor immune response

DAY 1 AGENDA

12.50	Dr Jerald Sadoff , Senior Advisor, Janssen Infectious Diseases and Vaccines Dr James Crowe , Director, Vanderbilt Vaccine Center Dr Bruce Gellin , President, Global Immunization, Sabin Vaccine Institute	Immunomic is addressing the challenges of viral targets in cancer Dr Teri Heiland , Co-Founder & Sr. Vice President of Research and Development, Immunomic Therapeutics	
1.20	Networking Lunch & Poster Session		
2.00	Lunchtime presentation & book signing: "Vaccines did not cause Rachel's Autism" Peter Hotez , President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine		
2.50	A live attenuated pertussis vaccine to prevent disease, colonization and transmission Dr Keith Rubin , CEO, ILiAD Biotechnologies	Next generation platform for the development of personalized synthetic cancer vaccines Dr Mark Findeis , Senior Director Research Biochemistry, agenus Inc.	Understanding which patients are most likely to responds using precision medicine tools - using MSI as a biomarker Dr Steven Townson , Oncology Scientific Director, Principal Scientist, Clinical Research Oncology Early Development, Merck Research Laboratories
3.20	New approaches are needed to develop RSV vaccines	Overcoming tumor immune suppression using a novel retroviral replicating vector Dr Asha Das , SVP & CMO, Tocagen Inc.	Clinical trial analysis - What end-points should we be using now that PFS is not robust and OS may be contaminated by cross-over? Dr Cristian Massacesi , Vice President Asset Team Leader, Immuno-Oncology, Pfizer
	MOSQUITO-BORNE DISEASES	T-CELL THERAPIES	INFECTIOUS DISEASES
3.50	Updates in the clinical development of a chikungunya vaccine Dr Lisa Danzig , CMO, PaxVax	The next wave: development of BCMA CAR-T therapies for multiple myeloma Dr Kristen Hege , Vice President, Translational Development, Hematology/ Oncology, Celgene	Challenges of conducting clinical trials during a pandemic
4.20	Afternoon Networking Break		
4.50	Progress towards licensure and deployment of a malaria vaccine Dr Stephen Hoffman , CEO & CSO, Sanaria	Clinical development of engineered T Cell therapies Bob Valamehr , Vice President of Cancer Immunotherapy, Fate Therapeutics	Getting Closer to the Market: BiondVax's Universal Flu Vaccine Pivotal Phase 3 Trial Dr Ron Babecoff , Founder, President & CEO, BiondVax Pharmaceuticals
5.10	PANEL Is there a future for arbovirus vaccines? MODERATOR: Peter Hotez , President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine	Strategies for the development of safer and more effective CAR-T therapies Dr Travis Young , Director, Protein Sciences, California	Clinical development of hard to develop vaccines
5.40	Dr Anna Durbin , Professor, International Health, Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health Dr Ted Tsai , Vice President, Immunizations, Science and Policy, Takeda Vaccines Additional panelists TBC*	Allogenic vs autologous CAR-T therapies - pros and cons Dr Hyam Levitsky , Former EVP & CSO, Juno Therapeutics (Now Celgene)	Challenges in early and late phase clinical development of vaccines
6.10	Chair closing remarks of day one followed by networking drinks reception		

DAY 2 AGENDA

	VACCINE DEVELOPMENT	IMMUNO-ONCOLOGY	DELIVERY, BIOPROCESSING & MANUFACTURING
	EMERGING & REEMERGING VACCINE TARGETS	THERAPEUTIC IMMUNOTHERAPY APPROACHES	VACCINE TECHNOLOGY & MANUFACTURE
08.30	Chair’s opening remarks	Chair’s opening remarks	Chair’s opening remarks
08.40	Strategies for preparedness and response to emerging and re-emerging diseases Dr Rick Bright , BARDA Director, Deputy Assistant Secretary for Preparedness & Response, HHS	Understanding mechanisms of resistance to checkpoint inhibitors - how can this inform combinatorial approaches? Dr Jean-Marie Bruey , Executive Director, Head of Oncology Biomarkers, Bristol-Myers Squibb	Challenges in bulk manufacture of live virus vaccines
09.10	A novel approach to developing single dose and safe vaccines for emerging infectious diseases Dr Farshad Guirakhoo , CSO, GeoVax	PANEL Immunotherapy in cancer - combinations are key Dr Teri Heiland , Co-Founder & Sr. Vice President of Research and Development, Immunomic Therapeutics Additional panelists TBC*	How could needle free vaccines change the way vaccines can be distributed and perceived in response to an emerging disease?
09.25			Long range production platform for pharmaceuticals: Application to CRM197 Dr Pascal Longchamp , Chief Corporate & Commercial Officer, Scarab Genomics Session title TBC*
09.40	Overview of the CEPI vaccine portfolio		A DNA vaccine platform to rapidly produce countermeasures against emerging viral threats Dr Kate Broderick , vice President, Research and Development, Inovio Pharmaceuticals
10.10	Morning Networking Break & Poster Session		
11:40	INTERACTIVE ROUNDTABLES Choose one of our roundtables for these interactive discussions with like-minded peers tackling the same challenges, for a full list go to the end of the agenda		
	Improving the accuracy of neoantigen identification	Considerations for successful cancer immunotherapy in aged hosts Dr Tyler Curiel , Professor Medicine, Hematology & Medical Oncology, UT Health San Antonio	Prospects and challenges for development of a Group A Streptococcal Vaccine Dr Victor Nizet , Chief of the Division of Host-Microbe Systems and Therapeutics, UCSD
	Clinical data integration - How do we deal with the volume of data generated by recent I-O trials?	How can we improve speed, delivery and cost of next generation cancer vaccines? Dr Daniel DeOliveira , Director of Pharmaceutical Sciences & Manufacturing, Genoclea	Legal considerations for partnering with government bodies, pharma and biotechs. Dr Charles Andres , Associate, Intellectual Property, Wilson, Sonsini, Goodrich & Rosati
	How can we streamline the vaccine manufacturing process to respond quickly to pandemics?	What are we doing to target potential responders or enrich for potential responders in immuno-oncology? Dr Harry Gruber , Co-founder and President of Science and Innovation, Tocagen Inc.	Clinical trial analysis - What end-points should we be using now that PFS is not robust and OS may be contaminated by cross-over?

DAY 2 AGENDA

	Where can the bridging take place between antibody manufacturing and vaccine manufacturing?	Development of predictive biomarkers to determine optimal combinations in precision immunotherapy Dr Sandip Patel , Co-Leader, Experimental Therapeutics, Deputy Director, San Diego Center for Precision Immunotherapy	Advances in adjuvant technology
	Discovery of pre-clinical genomic biomarkers of safety and efficacy in vaccine research, design and development	Surveillance systems to comprehensively monitor the use and safety of vaccines during pregnancy Dr Christina Chambers , Professor of Pediatrics, Founding Principal Investigator of Vaccines and Medications in Pregnancy Surveillance System, UCSD	What are investors looking for in emerging biotechs? Ken Solovay , Chief Operating Officer, ILiAD Biotechnologies Walter Greenblatt , Managing Director, Walter Greenblatt & Associates
If you are interested in leading a roundtable please contact Lauren Sheppard on +44(0)207 092 1211 or lauren.sheppard@terrapinn.com			
12.30	Networking Lunch & Poster Session		
	ANTIBODIES FOR INFECTIOUS DISEASES / AUTOIMMUNE	ANTIBODIES FOR CANCER	MANUFACTURING IMMUNOTHERAPIES
2.10	Human challenge studies for universal influenza monoclonal antibodies Dr Jerald Sadoff , Senior Adviser, Janssen Infectious Diseases and Vaccines	Early clinical development of antibody drug conjugates: challenges and opportunities Dr Steven Coats , Vice President R&D, MedImmune	Rapid cycle time, small-batch manufacturing technique for personalized cancer vaccines Dr Jayant Aphale , EVP Technical Operations, Gritstone Oncology
2.40	Development of trispecific antibodies for the treatment of HIV and potential for application to other infectious diseases Dr Richard Koup , Deputy Director, Vaccine Research Center, NIAID, NIH	A unique platform for the development of ADC, Bispecifics and monoclonal antibodies	Pharmaceutical development and manufacturing strategies for delivering highly personalized cancer vaccines to patients Dr Narinder Singh , Senior Vice President of Pharmaceutical Sciences and Manufacturing, Genoclea Biosciences
3.10	Platforms for antibody discovery, analysis and manufacture	Bispecific technology for multiple avenues of T-cell activation Dr John Dejarlais , Senior Vice President, Research and CSO, Xencor	Lowering production costs and process times through automation and process simplification (CART)
3.40	Afternoon Networking Break		
4.10	Harnessing natural immunity to create breakthrough therapies for infectious diseases Dr Sushma Shivaswamy , CSO, XBiotech USA Inc.	Bispecific therapies as monotherapies and in combination with checkpoint inhibitors Senior Representative, Regeneron Pharmaceuticals	ANTIBODY TECHNOLOGY & DELIVERY
			Development of novel antibody technologies to enable next generation therapeutics Dr Andrew Korytko , Lead External Innovation, Biotechnology Discovery Research, Eli Lilly Session title TBC*
4.40	Development of a monoclonal antibody against RSV	Novel IO-IO combinations that enhance anti-tumor activity	Platforms for the discovery and development of novel MABs - optimizing expression
5.10	Antibacterial monoclonal antibodies to combat serious bacterial infections	Novel targets for antibody immunotherapy	Bispecific Antibody Development Senior Representative, Regeneron Pharmaceuticals
5.40	Chair’s closing remarks of day two followed by networking drinks reception and meet & greet with key speakers		

DAY 3 AGENDA

	VACCINE DEVELOPMENT	IMMUNO-ONCOLOGY	FUNDING & PARTNERSHIPS
	IMMUNE PROFILING & MICROBIOME	THE CANCER MICROBIOME AND TUMOR MICROENVIRONMENT	FUNDING SOURCES
09.00	Chair's opening remarks	Chair's opening remarks	Chair's opening remarks
09.10	Predicting vaccine responses in the very young & old Dr Manish Sadarangani, Investigator, Assistant Professor, Department of Pediatrics, University of British Columbia, Director, Vaccine Evaluation Center, BC Children's Hospital	Single cell functionality serves as a predictive biomarker for overall survival of pancreatic cancer patients treated with GVAX vaccine Dr Will Singleterry, Director of Business Development, IsoPlexis	PANEL Partnering with federal labs: what you need to know MODERATOR: Dr Michael Salgaller, Supervisory Invention Development and Marketing Manager - IDM Unit, National Cancer Institute, National Institutes of Health Barry M. Datlof, Director, Medical Technology Transfer, U.S. Department of Defense Michael Mowatt, Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases Dr Charles Andres, Associate, Intellectual Property, Wilson, Sonsini, Goodrich & Rosati
09.40	FluoroSpot in vaccine research: multiplexing the sensitive ELISpot assay Dr Franco Pissani, Vice President and Scientific Advisor, Mabtech Inc.	Platforms for the analysis of the tumor microenvironment Senior Representative, IsoPlexis	
09.55	Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses in tuberculosis Dr Sangeeta Tiwari, Associate, Department of Microbiology and Immunology, Albert Einstein College of Medicine		
10.10	Understanding the immunological mechanisms that underlie severe adverse drug reactions Masahide Yano, Ph.D., Research Scientist, Center for Drug Evaluation and Research, FDA	A rational systematic approach to find combinations of pharmacologic and immune therapies that target identifiable oncogenic states Dr Pablo Tamayo, Co-Director, Cancer Center Genomics and Computational Biology Shared Resource, Professor, Division of Medical Genetics, UC San Diego School of Medicine	Opportunities to drive innovation in life sciences - turning basic scientific discoveries into new therapies for patients in need Dr Alex Szidon, Head, West Coast Innovation Hub and Assoc. Vice President Business Development & Licensing, Merck & Co. <i>Session title TBC*</i>
10.40	Morning Networking Break & Poster Session		
11.40	Investigation of how CD4-CTLs arise in humans provide valuable insights into the development of an effective HIV vaccine	The role of the microbiome in cancer vaccines and immunotherapies	NEW TECHNOLOGY SHOWCASE Present your solutions to a panel of seasoned investors for expert advice on how to catapult your business to the next level Michael Murray, Associate, Biotechnology Value Fund L.P. INVESTORS: Dr Steven Nagler, Executive Director, MedPro Investors Mr KC Stone, Managing Director, Head of Healthcare Investment Banking, BTIG Additional panelists TBC* TECHNOLOGY SHOWCASE 1 Supercharging immunotherapy targeting infectious disease & cancer Dr Torsten Mummenbrauer, SVP Business Development, Hookipa Biotech

DAY 3 AGENDA


11.55			TECHNOLOGY SHOWCASE 2
12.10	Using predictive models to interrogate human immunity Dr Tony Byers , Director Translational Sciences/VaxDesign, Sanofi Pasteur	PANEL Integrating our understanding of the tumor microenvironment and the microbiome to inform the development of I-O treatment Dr Maria Karasarides , Executive Director, ImmunoOncology, Regeneron Dr Theresa LaVallee , Head of Translational Medicine, Parker Institute for Cancer Immunotherapy Sandrine Miller-Montgomery , Executive Director, Center for Microbiome Innovation Dr Barbara Joyce-Shaikh , Project leader, Discovery Research, Merck Research Laboratories	TECHNOLOGY SHOWCASE 3
12.25			TECHNOLOGY SHOWCASE 4
12.40	Viral changes and antibody features that could provide a possible template for vaccine design		TECHNOLOGY SHOWCASE 5
12.55	Dr William Schief , Professor, Department of Immunology and Microbiology, The Scripps Research Institute		TECHNOLOGY SHOWCASE 6
1.10	Networking Lunch & Poster Session		
	DAY 3 PLENARY: THE FUTURE OF VACCINE AND IMMUNOTHERAPY DEVELOPMENT		
2.10	Chair’s opening remarks		
2.20	Accelerating progress of precision immunotherapy from laboratory to clinic through strategic collaborations	Dr Ezra Cohen, Professor of Medicine, UC San Diego Moores Cancer Center, Co-Director, San Diego Center for Precision Immunotherapy Dr Min Song, Program Director, Cancer Therapy Evaluation Program, Cancer Moonshot Implementation Team, National Cancer Institute, NCI Dr Catherine L. Higgins, Director of Scientific Program Management, Stand Up To Cancer	Dr Travis Young, Director, Protein Sciences, California Institute for Biomedical Research Dr Theresa LaVallee, Head of Translational Medicine, Parker Institute for Cancer Immunotherapy
3.20	Leveraging the power of AI & machine learning for accelerated vaccine & immunotherapy development	Dr John Baldoni, Senior Vice President, DPU Head, In Silico Discovery, GSK Pharmaceuticals Dr Larry Smarr, Director, California Institute for Telecommunications and Information Technology	
4.10	Chair’s Closing Remarks & End of Congress		

Agenda accurate to 14/06/2018.

Please see the website www.terrapinn.com/wvicwc-brochure for the most up-to-date agenda.

For more speaking information please contact: Lauren.Sheppard@terrapinn.com

The 350+ Attendees In 2018 Are Coming From:



Big Pharma And Biotechs Who Attended In 2017 Include:

AERAS Agenus Inc Amgen Astellas Pharma Inc Bavarian Nordic Baxter Biological E. Limited Boehringer Ingelheim Bristol-Myers Squibb Cellegene CEPI Department of Health and Human Services Eli Lilly and Company Emergent BioSolutions EpiVax Inc FDA FluGen Inc Genentech Genocera Biosciences GSK Vaccines Health Canada Icahn School of Medicine at Mount Sinai Immunomic Therapeutics Inovio Institut Pasteur Janssen Infectious Diseases and Vaccines La Jolla Infectious Disease Institute Mayo Clinic and Foundation Medicago MedImmune Inc Merck & Co. Merial Mitsubishi Tanabe Pharma Corporation Moderna Therapeutics National Cancer Institute New Link Genetics NIAID - NIH Novavax Parker Institute for Cancer Immunotherapy PATH Pfizer Sabin Vaccine Institute Sanaria Sanofi Pasteur SutroVax, Inc Takeda Pharmaceuticals The Bill & Melinda Gates Foundation The Human Vaccines Project The Jenner Institute - University of Oxford The Salk Institute Valneva Vanderbilt Vaccine Center Vaxart VBI Vaccines Inc Walter Reed Army Institute Of Research World Health Organisation Bharat Biotech GAVI UNICEF IAVI Human Vaccine Project CDC HHS Stanford University School of Medicine Scripps University

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

Networking Opportunities

A core focus of the event outside the conference sessions is for all attendees to be able to network and develop lasting relationships with each other to drive their businesses. We have several tools for this as follows:



PARTNERING TOOL

Please use this powerful platform and app to continue to set up meetings on-site with other delegates, as well as after the event where it will stay live to communicate. Create and maintain a public profile, request meetings with other members, manage a personalised schedule of event sessions and meetings, send private in-app messages to other members and much more.

Meetings already set up these will take place within the **exhibition area** at your allocated table that was pre-confirmed to you. Please turn up at the specified time for your meeting and keep within the time limit so that the next set of meetings can run on time as scheduled. If for any reason you need to change the time or contact the delegate you are meeting, this can be done in real time on the app.



NETWORKING DRINKS RECEPTION

It's not always about the conference sessions. Our themed evening networking drinks reception will allow you to unwind with your peers and continue conversations in good company.



NETWORKING LUNCHES

Our extended lunch periods in the exhibition hall will provide you with ample time to network between sessions. These lunch formats allow for more opportunities for casual conversations and introductions at your booth.



SCIENTIFIC POSTERS

Share previous unpublished research with leaders in the vaccine field within the dedicated Scientific Poster area. Taking place during the lunch on day one of the congress, the Poster Session will make it possible for you to answer questions and gain feedback.



NETWORKING MANAGER

If you come in as a high-level sponsor, leading up to the event you will be assigned your very own Networking Manager who will be at your beck and call to help you set up meetings in advance of your arrival to the event. Your meeting schedule will be based on your desired targets on the delegate list. On-site, the Networking Manager will facilitate your meetings in a designated area.



EXHIBITION STANDS

Take an exhibition stand to showcase your services, products and solutions to over 500 vaccine industry decision makers

Why Sponsor



SPEAKING OPPORTUNITIES

If your company is interested in delivering a thought leadership, education or case study presentation at the event, we have limited slots as per the following sponsorship packages.

Stand alongside top Vaccines & Immunotherapy decision makers from key Pharma, Biotech, Government, Academic/Research Institutions and non-profits, to make sure your company is front of mind to those who matter.



THOUGHT LEADERSHIP PRESENTATIONS

EXCLUSIVE KEYNOTE TITLE

Exclusive to one company only, you will have the opportunity to present in the KEYNOTE plenary alongside a handful of the very top vaccine industry thought leaders, and to an audience of over 350 decision makers.

No other company at the event will have the same chance to position itself in the same way in your area of expertise, so offering unparalleled visibility to demonstrate your offering as the leader in your field.

PLATINUM

Presenting to a more targeted vaccine audience in your specific area of expertise, this is an exclusive opportunity to be the session lead sponsor and one of the first speakers of the relevant conference track.



ROUNDTABLES

Host a roundtable of up to 15 industry professionals around key topics.



CASE STUDY PRESENTATIONS

GOLD

If you are looking for a platform to demonstrate and educate the leading vaccine decision makers of the full range of your services and capabilities, we have a few limited presentation opportunities within each targeted conference track to present in.



PANEL DISCUSSIONS

SILVER

Either chair one of the conference track sessions relevant for your business or join one of the limited relevant panel discussions.



TECHNOLOGY SHOWCASE

If you are a biotech or platform technology company, take the opportunity to present and showcase your latest work in the relevant conference agenda



BRANDING

Promote your brand to over 350 senior vaccine executives by taking up high impact exhibition and theatre branding at the show

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

THE EXHIBITION

Here's an overview of the floor plan. See the website for the most up-to-date version.

YOUR CUSTOMERS WILL BE THERE TO:

- Hear insights from the world's leading thinkers, practitioners and process disrupters
- Evaluate and buy the latest technologies
- Create new partnerships and gain investment
- Have fun and do business

WHAT THIS MEANS FOR YOUR BUSINESS:


Emerging science, technologies and collaborations are needed to make the necessary moves forward. As a provider of solutions to these issues, the event will provide a space for you to get in front of potential new customers from all walks of the vaccine & immunotherapy industry.

WHAT A GREAT OPPORTUNITY TO:

- Debut new solutions
- Improve your brand awareness
- Meet new prospective clients
- Maintain relationships

PURSUE AND PARTNER

- Thousands of formal and informal meetings over just three days
- 30+ scientific posters
- Three engaging networking lunches
- Two networking drinks receptions



Who should sponsor?

Contract Research Organisations

Contract Manufacture Organisations

Equipment

Technology and device manufacturers

Clinical Trial Site / Network

Platform Technology

Biotech

Pharma

Supply & Logistics

Bioanalytical / Data Companies

Consultants

"Well-organized, different audience in SD than the typical Boston/DC event, excellent approachability of attendees for networking"

VP
Commercial Development MicroMedicine

"Quality Speakers, Organization and Execution"

Lead Vaccine Validation Scientist Covance

"The concept of mixing two complimentary therapeutic areas was stellar and the speakers were also great."

Executive Director
ImmunoOncology Regeneron Pharmaceuticals

"Networking was excellent."

Director
R&D Immunocom Inc

"Novelty and depth of scientific presentations"

Director of Immunology
Cancer Vaccines & Immunotherapeutics
Pfizer

"Great topics, decent speaker list, right size."

Vice President
Business Development & Scientific
Advisor Mabtech

"The quality of the talks was excellent"

Director
Therapeutic Programs Ichor Medical
Systems, Inc

Get Involved

To exhibit, sponsor or speak at the event contact **Oliver Breed** on +44 (0)207 092 1156, or oliver.breed@terrapinn.com

2018 Sponsors & Exhibitors

